Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury-Reference-Cited by-同舟云学术

Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury

Published:2011-11 Issue:10 Volume:15 Page:1040-1048
ISSN:1090-3801
Container-title:European Journal of Pain
language:en
Short-container-title:

Author:

Anand Praveen,Shenoy Ravikiran,Palmer Joanne E.,Baines Amanda J.,Lai Robert Y.K.,Robertson Jonathan,Bird Nick,Ostenfeld Thor,Chizh Boris A.

Publisher

Wiley

Subject

Anesthesiology and Pain Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1016/j.ejpain.2011.04.005/fullpdf

Reference45 articles.

1. Heat shock protein 27 functions in inflammatory gene expression and transforming growth factor-beta-activated kinase-1 (TAK1)-mediated signaling;Alford;J Biol Chem,2007

2. TRPA1 receptor localisation in the human peripheral nervous system and functional studies in cultured human and rat sensory neurons;Anand;Neurosci Lett,2008

3. The potential role of nerve growth factor (NGF) in painful neuromas and the mechanism of pain relief by their relocation to muscle;Atherton;J Hand Surg Br,2006

4. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion?;Attal;Pain,2008

5. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function;Badger;J Pharmacol Exp Ther,1996

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of kynurenines in migraine-related neuroimmune pathways;The Journal of Headache and Pain;2024-08-07

2. Platelet transcription factors license the pro-inflammatory cytokine response of human monocytes;EMBO Molecular Medicine;2024-07-08

3. Targeting Efferocytosis in Inflammaging;Annual Review of Pharmacology and Toxicology;2024-01-23

4. p38 mitogen-activated protein kinase inhibitors;Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy;2024

5. CNS-Active p38α MAPK Inhibitors for the Management of Neuroinflammatory Diseases: Medicinal Chemical Properties and Therapeutic Capabilities;Molecular Neurobiology;2023-12-02